Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages en Stemming true Single Family Member true

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents

Full Query

IC:C07

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2020/102857METHODS FOR MANAGEMENT OF WEIGHT
WO 28.05.2020
Int.Class A61K 31/5517
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
55having seven-membered rings, e.g. azelastine, pentylenetetrazole
551having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
55131,4-Benzodiazepines, e.g. diazepam
5517condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
Appl.No PCT/AU2019/051284 Applicant THE UNIVERSITY OF SYDNEY Inventor MCGREGOR, Iain Stewart
Disclosed herein are methods for causing weight loss, for managing weight, and for suppressing an appetite for food in a subject, and methods for reducing the consumption of food by a subject by administering the compounds, or pharmaceutically acceptable salts or prodrugs thereof, of the invention.
2.WO/2020/103777INTERLEUKIN 21 PROTEIN (IL21) MUTANT AND USE THEREOF
WO 28.05.2020
Int.Class C07K 14/54
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
52Cytokines; Lymphokines; Interferons
54Interleukins (IL)
Appl.No PCT/CN2019/119088 Applicant HYQUO MOLECULE (BEIJING) TECHNOLOGY CO., LTD Inventor ZHANG, Xin
Provided in the present invention are an interleukin 21 protein (IL21) mutant and a use thereof. In the mutant, both ILE at position 16 and SER at position 70 of wild-type IL21 are mutated into CYS, and disulfide bonds are formed between the two mutated CYSs. Also provided is a fusion protein containing the IL21 protein mutant. The IL21 protein mutant or fusion protein can be used for regulating or activating immunity, resisting tumors and promoting the differentiation and proliferation of B cells, T cells or NK cells.
3.WO/2020/103817TGF-βR1 INHIBITOR AND USE THEREOF
WO 28.05.2020
Int.Class C07D 401/14
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
14containing three or more hetero rings
Appl.No PCT/CN2019/119413 Applicant NANJING SANHOME PHARMACEUTICAL CO., LTD. Inventor WANG, Yong
The present invention belongs to the field of medicinal chemistry, and relates to a class of compounds as a TGF-βR1 inhibitor and the use thereof. Specifically, provided in the present invention are a compound shown in formula I, or an isomer, a pharmaceutically acceptable salt, a solvate, a crystal or a prodrug thereof, a preparation method therefor and a pharmaceutical composition containing these compounds, and the use of these compounds or compositions for treating and/or preventing TGF-βR1-related diseases, such as cancers, tissue proliferative diseases, fibrosis and inflammatory diseases. The compounds of the present invention exhibit significant inhibitory activity on TGF-βR1 kinases, and have very strong potential to be therapeutic agents for TGF-βR1-related diseases. (I)
4.WO/2020/103897HETEROCYCLIC FUSED PYRIMIDINE DERIVATIVE, PHARMACEUTICAL COMPOSITION THEREOF, AND APPLICATION THEREOF
WO 28.05.2020
Int.Class A61K 31/7064
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7042Compounds having saccharide radicals and heterocyclic rings
7052having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
706containing six-membered rings with nitrogen as a ring hetero atom
7064containing condensed or non-condensed pyrimidines
Appl.No PCT/CN2019/119899 Applicant SHANGHAI DE NOVO PHARMATECH CO., LTD. Inventor ZHAO, Zhiming
A heterocyclic fused pyrimidine derivative, a pharmaceutical composition thereof, and an application thereof. A heterocyclic fused pyrimidine derivative (I), and an isomer, prodrug, stable isotope derivative, or pharmaceutically acceptable salts thereof have the following structure. The heterocyclic fused pyrimidine derivative can inhibit the ATR level well both in vivo and in vitro. Furthermore, the heterocyclic fused pyrimidine derivative can be also used for effectively treating diseases caused by the abnormal ATR level such as cancer.
5.WO/2020/104197A PROCESS FOR THE SYNTHESIS OF UREA
WO 28.05.2020
Int.Class C07C 273/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
CACYCLIC OR CARBOCYCLIC COMPOUNDS
273Preparation of urea or its derivatives, i.e. compounds containing any of the groups the nitrogen atoms not being part of nitro or nitroso groups
02of urea, its salts, complexes or addition compounds
04from carbon dioxide and ammonia
Appl.No PCT/EP2019/080471 Applicant CASALE SA Inventor MARRONE, Leonardo
A process for synthesis of urea from CO2 and NH3 wherein a steam flow (13) produced in the condenser (3) of a high-pressure synthesis loop is compressed to raise its pressure and temperature before using the steam as a heat source for a downstream step of the process.
6.WO/2020/104267α2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONISTS FOR THE TREATMENT OF SLEEP APNEA
WO 28.05.2020
Int.Class C07D 401/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02containing two hetero rings
04directly linked by a ring-member-to-ring- member bond
Appl.No PCT/EP2019/081134 Applicant BAYER AKTIENGESELLSCHAFT Inventor DELBECK, Martina
The present invention relates to α2-Adrenoceptor subtype C (alpha-2C) antagonists, in particular substituted bipiperidinyl derivatives of formula (I) for the use in a method for the treatment and/or prophylaxis of sleep-related breathing disorders, preferably obstructive and central sleep apneas and snoring. Formula (I) in which Y is a group (A) or (B).
7.WO/2020/104627PHOTOCHEMICALLY INDUCED CONJUGATION OF RADIOMETALS TO SMALL MOLECULES, PEPTIDES AND NANOPARTICLES IN A SIMULTANEOUS ONE-POT REACTION
WO 28.05.2020
Int.Class C07C 247/16
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
CACYCLIC OR CARBOCYCLIC COMPOUNDS
247Compounds containing azido groups
16with azido groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
Appl.No PCT/EP2019/082159 Applicant UNIVERSITÄT ZÜRICH Inventor HOLLAND, Jason Philip
The invention relates to a method for labeling a target compound with a radiometal by photochemically induced conjugation. Furthermore, a chelating compound for use in said method is provided. The chelating compound is characterized by an aryl-azide moiety which can be photoconjugated to a target compound and a chelator moiety which can be radiolabelled. The photoconjugaton and radiolabelling are both performed at basic pH performed in a simultaneous one-pot reaction.
8.WO/2020/104657NLRP3 INHIBITORS
WO 28.05.2020
Int.Class A61P 3/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3Drugs for disorders of the metabolism
Appl.No PCT/EP2019/082231 Applicant INFLAZOME LIMITED Inventor COOPER, Matthew
The present application relates to compounds with NLRP3inhibitory activity and to associated salts, solvates, prodrugs and pharmaceutical compositions. The present application further relates to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by NLRP3inhibition.
9.WO/2020/104687USE OF POLYHYDROXYAROMATIC COMPOUNDS FOR THE TREATMENT OF FIBROUS AMINO ACID BASED SUBSTRATES
WO 28.05.2020
Int.Class C07C 69/88
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
CACYCLIC OR CARBOCYCLIC COMPOUNDS
69Esters of carboxylic acids; Esters of carbonic or haloformic acids
76Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a six-membered aromatic ring
84of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring
88with esterified carboxyl groups
Appl.No PCT/EP2019/082310 Applicant MOMENTIVE PERFORMANCE MATERIALS GMBH Inventor
This invention relates to the use of polyhydroxyaromatic compounds for the treatment of fibrous amino acid based substrates, preferred hair, new polyhydroxyaromatic compounds, aqueous compositions comprising the polyhydroxyaromatic compounds, cosmetic compositions comprising the polyhydroxyaromatic compounds, in particular hair care compositions, and a process for the treatment of hair comprising the use of said cosmetic compositions.
10.WO/2020/104697STABLE VACCINE AGAINST CLOSTRIDIUM DIFFICILE
WO 28.05.2020
Int.Class C07H 17/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
17Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
04Heterocyclic radicals containing only oxygen as ring hetero atoms
Appl.No PCT/EP2019/082331 Applicant VAXXILON AG Inventor EMMADI, Madhu
The present invention relates to a synthetic saccharide of general formula (I) that is related to Clostridium difficile PS-II cell-surface polysaccharide and conjugate thereof. Said synthetic saccharide, said conjugate and pharmaceutical composition containing said synthetic saccharide or said conjugate are useful for prevention and/or treatment of diseases associated with Clostridium difficile. Furthermore, the synthetic saccharide of general formula (I) is useful as marker in immunological assays for detection of antibodies against Clostridium difficile bacteria.